Table 2

Patient characteristics of patient with final BM cohort

CharacteristicsBCNSCLCPC
N5598941013
Follow-up: median days (Q1–Q3)458 (128–933)87 (37–205)682 (357)
Age at BM diagnosis, median (Q1–Q3)65 (52–76)69 (62–77)75 (62–77)
Stage IV at primary cancer diagnosis30%86%72%
History of SRE at BM diagnosis
In the 56-day pre-BM-diagnosis period35%94%25%
Less than 16 days before BM diagnosis1%3%1%
Within 16–32 days before BM diagnosis3%8%5%
BTANo BTABTANo BTABTANo BTA
N294265117777121892
Sex–female100%100%45%45%0%0%
Primary cancer stage IV29%30%85%86%74%71%
CRPC diagnosis#*#*#*#*82%56%
At BM diagnosis#####*#*
ECOG present64%39%86%82%30%19%
ECOG 0–294%81%67%49%27%18%
eGFR† median (Q1–Q3)81 (67–90)83 (60–90)90 (72–90)86 (66–90)82 (65–90)73 (57–90)
eGFR† <6015%22%14%17%17%26%
Hypercalcaemia‡ classification at BM diagnosis
<2.75 mmol/L90.51%88.33%82.20%94.27%75.21%71.65%
Mild3.05%#6.78%2.00%0.00%#
Moderate##6.78%#0.00%#
Severe#0.00%##0.00%0.00%
Missing/Unknown#8.95%#2.40%24.79%27.76%
Renal disease
Yes#3.4%#3.6%0.8%3.8%
Missing70.4%56.6%23.1%21.5%57.0%47.2%
CCI
021.4%31.3%57.3%51.1%33.1%39.4%
15.4%4.2%14.5%16.6%4.1%5.9%
2#4.9%#6.8%5.0%4.9%
3+#3.0%#4.0%0.8%2.6%
Missing70.4%56.6%23.1%21.5%57.0%47.2%
Oestrogen receptor status
Positive84.4%72.1%####
Missing#3.0%
Progesterone receptor status
Positive65.0%55.1%####
Missing6.1%6.4%
HR/HER2 status
HR–/HER2–10.0%17.0%####
HR–/HER2+3.4%6.8%####
HR+/HER2–58.2%46.4%####
HR+/HER2+5.8%5.3%####
Missing22.8%24.5%####
EGFR mutation
Pathogenic##9.4%5.2%##
Wildtype##45.3%29.6%##
Missing##45.3%65.3%##
ALK mutation
Pathogenic###2.2%##
Wildtype##41.0%21.8%##
Missing##55.6%76.1%##
PD-L1 mutation
High (50%)###4.1%##
Intermediate (1–49%)##10.3%###
Low (<1%)##13.7%5.0%##
Not done##25.6%19.1%##
missing##44.4%68.5%##
Histopathological stage
Squamous-cell carcinoma##23.1%15.6%##
Other specified NSCLC###2.7%##
NSCLC NOS##12%16.6%##
Non-squamous NSCLC##49.6%39.6%##
missing##11.1%25.5%##
Therapy before BTA administration‡
None12.9%10.6%59.8%68.5%63.6%72.9%
RT##*#2.3%8.3%6.1%
RT and surgery15.0%11.7%#1.9%5.8%4.2%
SACT¶#07.7%2.3%##*
SACT and RT#0#2.1%#0.8%
SACT and surgery11.9%7.9%#3.5%##
SACT, RT and surgery32.7%33.2%6.8%3.2%##
Surgery25.9%34.7%13.7%16.2%16.5%14.6%
  • *#Means <6 patients.

  • †eGFR units: mL/min/1.73 m2).

  • ‡The level of hypercalcaemia was based on the following serum calcium levels (mmol/L): mild 2.75–3.00; moderate 3.00–3.40; severe 3.40+.

  • §The time period for these therapies includes the time from primary cancer to BM diagnosis.

  • ¶SACT was cancer-specific and included chemotherapy, endocrine therapy and targeted therapy.

  • ALK, anaplastic lymphoma kinase; BM, bone metastasis; BTA, bone-targeting agent; CCI, Charlson Comorbidity Index; CRPC, castration-resistant prostate cancer; ECOG, Eastern Cooperative Oncology Group; eGFR, estimated glomerular filtration rate; HER, human epidermal growth factor receptor; HR, hormone receptor; NA, not available; NOS, non-otherwise specified; NSCLC, non-small cell lung cancer; PD-L1, programmed cell death receptor ligand-1; RT, radiotherapy; SACT, systemic anticancer therapy.